CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today...
Related Questions
How do the interim financial results and cash runway compare to the company's guidance and analyst expectations?
What impact will the reported progress in the antibody therapeutic pipeline have on future revenue and regulatory milestones?
Are there any indications of upcoming share issuances, partnerships, or strategic changes that could affect dilution or market perception?